Abstract | OBJECTIVE: DESIGN: Systematic review of the literature and meta-regression. METHODS: Electronic databases were searched for controlled and uncontrolled studies and economic evaluations relating to the use of SCS in patients with either CRPS type I or II. RESULTS: One randomised controlled trial, 25 case series and one cost-effectiveness study were included. In the randomised controlled trial in type I CRPS patients, SCS therapy lead to a reduction in pain intensity at 24 months of follow-up (mean change in VAS score -2.0), whereas pain was unchanged in the control group (mean change in VAS score 0.0) (p<0.001). In the case series studies, 67% (95% CI 51%, 84%) of type I and type II CRPS patients implanted with SCS reported pain relief of at least 50% over a median follow-up period of 33 months. No statistically significant predictors of pain relief with SCS were observed in multivariate meta-regression analysis across studies. An economic analysis based on the randomised controlled trial showed a lifetime cost saving of approximately 58,470 (60,800 US dollars) with SCS plus physical therapy compared with physical therapy alone. The mean cost per quality-adjusted life-year at 12-month follow-up was 22,580 (23,480 US dollars). CONCLUSIONS: SCS appears to be an effective therapy in the management of patients with CRPS type I (Level A evidence) and type II (Level D evidence). Moreover, there is evidence to demonstrate that SCS is a cost-effective treatment for CRPS type I.
|
Authors | Rod S Taylor, Jean-Pierre Van Buyten, Eric Buchser |
Journal | European journal of pain (London, England)
(Eur J Pain)
Vol. 10
Issue 2
Pg. 91-101
(Feb 2006)
ISSN: 1090-3801 [Print] England |
PMID | 16310712
(Publication Type: Journal Article, Review, Systematic Review)
|
Topics |
- Complex Regional Pain Syndromes
(economics, therapy)
- Cost-Benefit Analysis
- Electric Stimulation Therapy
(economics)
- Humans
- Prognosis
- Spinal Cord
|